Study, year
|
country
|
design
|
Subjects, n,
T/C
|
gender
|
Mean age years
|
Underline diseases
|
Study duration
days
|
Type of intervention in intervention group
|
Type of intervention in control group
|
Outcome measured
|
(Elamin et al., 2012), |
USA |
Parallel |
11/11 |
M/F |
53.3 |
Medical-
Surgical Patients with ARDS |
7 |
Oxepa® Ross Labs, Chicago, Illinois,
USA |
Pulmocare® Ross Labs, Chicago, Illinois, USA |
Duration of ICU
stay, level of oxygenation, duration of mechanical ventilation, SOFA and
MOD score, 28 days mortality |
(Gadek et al., 1999) |
USA |
Parallel |
45/43 |
M/F |
63 |
ARDS patients |
7 |
The lipid blend provides EPA and docosahexaenoic acid from fish
oil and GLA from borage oil |
high-fat, low-carbohydrate enteral
nutrition formula |
Duration of ICU stay, level of oxygenation, duration
of mechanical ventilation, length of hospital stay, ventilator free
days, ICU free days, 28 days mortality |
(Grau-Carmona et al., 2011) |
Spain |
Parallel |
61/71 |
M/F |
63.5 |
Septic patients with ALI or ARDS |
21 |
Oxepa Abbott Labs |
Ensur Abbott
Labs |
Duration of ICU stay, level of oxygenation, duration of
mechanical ventilation, 28 days mortality |
(Kagan et al., 2015) |
Israel |
Parallel |
62/58 |
M/F |
40.72 |
severe
multiple trauma |
8 |
Oxepa; Ross Laboratories |
Pulmocare; Ross
laboratories, Chicago, IL |
Duration of ICU stay, level of oxygenation,
duration of mechanical ventilation, length of hospital stay, SOFA and
MOD score, 28 days mortality |
(Pontes-Arruda et al., 2011) |
Brazil |
Parallel |
53/53 |
M/F |
71 |
Early sepsis |
7 |
EPA/GLA diet |
isocaloric, isonitrogenous control
diet |
Duration of ICU stay, duration of mechanical ventilation, length
of hospital stay, ICU free days, SOFA and MOD score, 28 days
mortality |
(Pontes-Arruda et al., 2006) |
Brazil |
Parallel |
55/48 |
M/F |
66.1 |
ventilated patients with severe sepsis and septic shock |
7 |
enteral
nutrition enriched with EPA, GLA, |
isonitrogenous and isocaloric
control diet |
level of oxygenation, ICU free days, ventilator free
days, 28 days mortality |
(Rice et al., 2011) |
USA |
Parallel |
143/129 |
M/F |
59 |
ALI patients |
28 |
enteral supple- mentation of n-3 fatty acids, GLA, and
antioxidants |
isocaloric-isovolemic carbohydrate-rich control |
Duration of ICU stay, ICU free days, ventilator free days, 28 days
mortality |
(Shirai et al., 2015) |
Japan |
Parallel |
23/23 |
M/F |
72.5 |
sepsis-induced ARDS |
14 |
Oxepa™; Abbott Nutrition, Tokyo, Japan |
Ensure Liquid™; Abbott Nutrition, Tokyo, Japan |
Duration of ICU stay,
level of oxygenation, duration of mechanical ventilation, ICU free days,
ventilator free days, SOFA and MOD score, 28 days
mortality |
(Singer et al., 2006) |
Israel |
Parallel |
44/44 |
M/F |
59.6 |
ventilated patients with ALI |
14 |
Oxepa, Ross Laboratories |
high-fat,
low-carbohydrate, enteral formula (Pulmo- care, Ross Laboratories,
Chicago, IL) |
level of oxygenation, duration of mechanical ventilation,
length of hospital stay, 28 days mortality |
(Tsukahara et al., 2014) |
Japan |
Parallel |
30/32 |
M/F |
63.8 |
Head
and Neck Cancer Surgery Patients |
8 |
Oxepa®; Abbott Japan |
Ensure® H;
Abbott Japan, Tokyo, Japan |
Duration of ICU stay, length of hospital
stay, |
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|
1RCTs, randomized controlled trials; Duration refers to the duration of
treatment. T/C, treatment/control. M, male; F, female; ARDS, acute
respiratory distress syndrome; ALI
, acute lung injury; ICU, intensive care unit; SOFA, sequential organ
failure assessment; MOD, multiple organ disfunction
|